NCT00324116 - Evaluation Of Safety And Efficacy Of 0.3 Mg/Eye Macugen In Patients With Small Age-Related Macular Degeneration Lesions | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 31, 2006

Primary Completion Date

August 31, 2008

Study Completion Date

August 31, 2008

Conditions

Macular Degeneration

Interventions

DRUG

pegaptanib sodium (Macugen)

0.3 MG/eye pegaptanib IB sodium by intravitreous injection given every 6 weeks for 54 weeks.

Trial Locations (34)

13008

Pfizer Investigational Site, Marseille

16110

Pfizer Investigational Site, La Rochefoucauld

21033

Pfizer Investigational Site, Dijon

25030

Pfizer Investigational Site, Besançon

29200

Pfizer Investigational Site, Brest

31054

Pfizer Investigational Site, Toulouse

31200

Pfizer Investigational Site, Toulouse

33076

Pfizer Investigational Site, Bordeaux

33100

Pfizer Investigational Site, Bordeaux

34000

Pfizer Investigational Site, Montpellier

34070

Pfizer Investigational Site, Montpellier

38140

Pfizer Investigational Site, Rives

38700

Pfizer Investigational Site, La Tronche

44093

Pfizer Investigational Site, Nantes

44819

Pfizer Investigational Site, Saint-Herblain

49933

Pfizer Investigational Site, Angers

54000

Pfizer Investigational Site, Nancy

59800

Pfizer Investigational Site, Lille

64100

Pfizer Investigational Site, Bayonne

67000

Pfizer Investigational Site, Strasbourg

67091

Pfizer Investigational Site, Strasbourg

68070

Pfizer Investigational Site, Mulhouse

69003

Pfizer Investigational Site, Lyon

69317

Pfizer Investigational Site, Lyon

71018

Pfizer Investigational Site, Mâcon

75006

Pfizer Investigational Site, Paris

75015

Pfizer Investigational Site, Paris

75557

Pfizer Investigational Site, Paris

75940

Pfizer Investigational Site, Paris

76000

Pfizer Investigational Site, Rouen

86021

Pfizer Investigational Site, Poitiers

87042

Pfizer Investigational Site, Limoges

90016

Pfizer Investigational Site, Belfort

94010

Pfizer Investigational Site, Créteil